Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results.

H. Peter Vollmers, U. Zimmermann, Veit Krenn, W. Timmermann, Bertram Illert, Frank Hensel, R. Schulte Hermann, A. Thiede, Mathias Wilhelm, H. Rückle-Lanz,

Oncology Reports · 1998 · 52 citations · 0 references

Concepts

Abstract

In a first clinical trial with the apoptosis-inducing human antibody SC-1 eight patients with poorly differentiated stomach adenocarcinoma of diffuse-type received 20 or 30 mg of purified SC-1 antibody intravenously, followed 24 or 48 h later by gastrectomy and lymphadenectomy. In seven cases a significant induction of apoptotic activity was measured in primary tumors as compared with earlier biopsy material and in five patients a significant regression of tumor mass could be determined histopathologically. No toxic crossreactivity was observed with normal tissue or organs of patients.